Swiss Perf Index to include Newron

27 April 2008

The SWX Swiss Exchange has announced that Italy-based Newron Pharmaceuticals is to be included in the Swiss Performance Index with a free float of 100%.

The SWX has approved the firm's application and its listing will begin on May 6. Companies wth a primary listing on the SWX will be able to join the SPI as of May 1. The index currently covers roughly 240 companies.

The news follows an announcement that fellow Italian company Bioxell will be included in the SPI under the same terms and details.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight